Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.1667.

Several equities analysts have recently commented on IMNM shares. Truist Financial upped their target price on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Barclays initiated coverage on Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th.

Immunome Stock Down 3.8%

Shares of IMNM opened at $22.01 on Friday. Immunome has a twelve month low of $8.66 and a twelve month high of $27.65. The stock has a market capitalization of $2.49 billion, a P/E ratio of -9.25 and a beta of 2.07. The company has a 50 day moving average of $21.00 and a 200-day moving average of $21.94.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts anticipate that Immunome will post -2.06 earnings per share for the current fiscal year.

Insider Activity

In other Immunome news, Director Jean Jacques Bienaime acquired 10,500 shares of Immunome stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $19.45 per share, with a total value of $204,225.00. Following the completion of the purchase, the director directly owned 43,415 shares of the company’s stock, valued at $844,421.75. This represents a 31.90% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company, valued at $985,094.51. This trade represents a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 472,142 shares of company stock worth $10,262,648. 7.21% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently added to or reduced their stakes in IMNM. KBC Group NV bought a new stake in shares of Immunome in the first quarter worth $60,000. Strs Ohio bought a new position in Immunome during the 4th quarter worth $64,000. Assetmark Inc. raised its position in Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Immunome during the 4th quarter worth about $121,000. Finally, BNP Paribas Financial Markets lifted its holdings in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.